nateglinide

[nah-teg´lĭ-nīd] an antidiabetic agent that lowers blood glucose concentrations by stimulating the release of insulin from pancreatic islet beta cells; administered orally in the treatment of type 2 diabetes mellitus, either alone or in combination with metformin.

nateglinide

Starlix

Pharmacologic class: Amino acid derivative

Therapeutic class: Hypoglycemic

Pregnancy risk category C

Action

Decreases blood glucose level by stimulating insulin secretion from pancreatic beta cells; interacts with calcium and potassium channels in pancreas

Availability

Tablets: 60 mg, 120 mg

Indications and dosages

➣ To decrease glucose levels in type 2 (non-insulin-dependent) diabetes mellitus not adequately controlled by diet and exercise

Adults: 120 mg P.O. t.i.d. up to 30 minutes before meals, or 60 mg P.O. t.i.d. if patient is near glycosylated hemoglobin (HbA1c) goal

Contraindications

• Hypersensitivity to drug or its components

• Diabetic ketoacidosis

• Type 1 (insulin-dependent) diabetes mellitus

Precautions

Use cautiously in:

• renal or hepatic impairment, adrenal or pituitary insufficiency

• elderly or malnourished patients

• pregnant or breastfeeding patients.

Administration

• Give 30 minutes before meals. If meal is missed, don't give dose.

• Know that drug may be given alone or with metformin.

Adverse reactions

CNS: dizziness

GI: diarrhea

Metabolic: hypoglycemia

Musculoskeletal: back pain, joint pain

Respiratory: upper respiratory tract infection, bronchitis, coughing

Other: flulike symptoms, trauma

Interactions

Drug-drug. Beta-adrenergic blockers, MAO inhibitors, nonsteroidal antiinflammatory drugs, salicylates: increased hypoglycemic effect

Corticosteroids, sympathomimetics, thiazides, thyroid products: reduced hypoglycemic effect

Drug-diagnostic tests. Glucose: decreased level

Patient monitoring

• Monitor blood glucose and HbA1c levels.

• Assess pulmonary status for bronchitis, upper respiratory infection, and flulike signs and symptoms.

• Monitor musculoskeletal status. Check for back pain and arthropathy.

• Note GI complaints, and identify nutritional deficiencies.

Patient teaching

• Instruct patient to take dose up to 30 minutes before each main meal.

• Advise patient not to skip a meal. If he does, tell him to also skip accompanying nateglinide dose, to prevent hypoglycemia.

• Teach patient how to monitor blood and urine for glucose and ketones, as prescribed.

• Instruct patient to report adverse CNS effects and signs and symptoms of respiratory infection.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects sensation and balance.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

nateglinide

(nə-tĕg′lĭ-nīd′)n. An oral hypoglycemic drug, C₁₉H₂₇NO₃, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.

单词	nateglinide
释义	nateglinide na·teg·li·nide N5030175 (nə-tĕg′lĭ-nīd′)n. An oral hypoglycemic drug, C₁₉H₂₇NO₃, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes. [nate-, origin unknown + -glinide, antidiabetic drug suff.; see repaglinide.] nateglinide nateglinide [nah-teg´lĭ-nīd] an antidiabetic agent that lowers blood glucose concentrations by stimulating the release of insulin from pancreatic islet beta cells; administered orally in the treatment of type 2 diabetes mellitus, either alone or in combination with metformin. nateglinide Starlix *Pharmacologic class:* Amino acid derivative *Therapeutic class:* Hypoglycemic *Pregnancy risk category C* Action Decreases blood glucose level by stimulating insulin secretion from pancreatic beta cells; interacts with calcium and potassium channels in pancreas Availability Tablets: 60 mg, 120 mg Indications and dosages ➣ To decrease glucose levels in type 2 (non-insulin-dependent) diabetes mellitus not adequately controlled by diet and exercise Adults: 120 mg P.O. t.i.d. up to 30 minutes before meals, or 60 mg P.O. t.i.d. if patient is near glycosylated hemoglobin (HbA1c) goal Contraindications • Hypersensitivity to drug or its components • Diabetic ketoacidosis • Type 1 (insulin-dependent) diabetes mellitus Precautions Use cautiously in: • renal or hepatic impairment, adrenal or pituitary insufficiency • elderly or malnourished patients • pregnant or breastfeeding patients. Administration • Give 30 minutes before meals. If meal is missed, don't give dose. • Know that drug may be given alone or with metformin. Adverse reactions CNS: dizziness GI: diarrhea Metabolic: hypoglycemia Musculoskeletal: back pain, joint pain Respiratory: upper respiratory tract infection, bronchitis, coughing Other: flulike symptoms, trauma Interactions Drug-drug. Beta-adrenergic blockers, MAO inhibitors, nonsteroidal antiinflammatory drugs, salicylates: increased hypoglycemic effect Corticosteroids, sympathomimetics, thiazides, thyroid products: reduced hypoglycemic effect Drug-diagnostic tests. Glucose: decreased level Patient monitoring • Monitor blood glucose and HbA1c levels. • Assess pulmonary status for bronchitis, upper respiratory infection, and flulike signs and symptoms. • Monitor musculoskeletal status. Check for back pain and arthropathy. • Note GI complaints, and identify nutritional deficiencies. Patient teaching • Instruct patient to take dose up to 30 minutes before each main meal. • Advise patient not to skip a meal. If he does, tell him to also skip accompanying nateglinide dose, to prevent hypoglycemia. • Teach patient how to monitor blood and urine for glucose and ketones, as prescribed. • Instruct patient to report adverse CNS effects and signs and symptoms of respiratory infection. • Caution patient to avoid driving and other hazardous activities until he knows how drug affects sensation and balance. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above. nateglinide (nə-tĕg′lĭ-nīd′)n. An oral hypoglycemic drug, C₁₉H₂₇NO₃, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.
随便看	alizarin indicator alizarin purpurin alizarin red alizarin red s alizarin yellow aliákmon alj alja al-jabal river al-jadida al- jafura al- jaghbub al jamaa al islamiya al jama'a al-islamiyyah al-muqatilah bi-libya al-jama'a al-islamiyyah al-muqatilah bi-libya al-jamaa islamiya aljama mosque aljamiado learning technologies al-janjaweed al- jawf al-jawlan al jaza'ir al jazair al-jaza'ir al jazeera

nateglinide

na·teg·li·nide

nateglinide

nateglinide

nateglinide

Action

Availability

Indications and dosages

Contraindications

Precautions

Administration

Adverse reactions

Interactions

Patient monitoring

Patient teaching

nateglinide